Literature DB >> 24900337

Nitric oxide donor doxorubicins accumulate into Doxorubicin-resistant human colon cancer cells inducing cytotoxicity.

Konstantin Chegaev1, Chiara Riganti2, Loretta Lazzarato1, Barbara Rolando1, Stefano Guglielmo1, Ivana Campia2, Roberta Fruttero1, Amalia Bosia2, Alberto Gasco1.   

Abstract

Products 4 and 5, obtained by conjugation of doxorubicin with nitric oxide (NO) donor nitrooxy and phenylsulfonyl furoxan moieties, respectively, accumulate in doxorubicin-resistant human colon cancer cells (HT29-dx), inducing high cytotoxicity. This behavior parallels the ability of the compounds to generate NO, detected as nitrite, in these cells. Preliminary immunoblotting studies suggest that the mechanism that underlies the cytotoxic effect could involve inhibition of cellular drug efflux due to nitration of tyrosine residues of the MRP3 protein pump.

Entities:  

Keywords:  Multidrug resistance; P-glycoprotein; doxorubicin; nitric oxide

Year:  2011        PMID： 24900337      PMCID： PMC4018161          DOI： 10.1021/ml100302t

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


  14 in total

Review 1.  Multidrug resistance in cancer: role of ATP-dependent transporters.

Authors:  Michael M Gottesman; Tito Fojo; Susan E Bates
Journal:  Nat Rev Cancer       Date:  2002-01       Impact factor: 60.716

Review 2.  Perspectives of P-glycoprotein modulating agents in oncology and neurodegenerative diseases: pharmaceutical, biological, and diagnostic potentials.

Authors:  Nicola Antonio Colabufo; Francesco Berardi; Mariangela Cantore; Marialessandra Contino; Carmela Inglese; Mauro Niso; Roberto Perrone
Journal:  J Med Chem       Date:  2010-03-11       Impact factor: 7.446

3.  Phenylsulfonylfuroxans as modulators of multidrug-resistance-associated protein-1 and P-glycoprotein.

Authors:  Roberta Fruttero; Marco Crosetti; Konstantin Chegaev; Stefano Guglielmo; Alberto Gasco; Francesco Berardi; Mauro Niso; Roberto Perrone; Maria Antonietta Panaro; Nicola Antonio Colabufo
Journal:  J Med Chem       Date:  2010-08-12       Impact factor: 7.446

Review 4.  Mechanisms of cancer drug resistance.

Authors:  Michael M Gottesman
Journal:  Annu Rev Med       Date:  2002       Impact factor: 13.739

5.  Hypoxia induced resistance to doxorubicin in prostate cancer cells is inhibited by low concentrations of glyceryl trinitrate.

Authors:  Lisa J Frederiksen; D Robert Siemens; Jeremy P Heaton; Lori R Maxwell; Michael A Adams; Charles H Graham
Journal:  J Urol       Date:  2003-09       Impact factor: 7.450

6.  RhoA silencing reverts the resistance to doxorubicin in human colon cancer cells.

Authors:  Sophie Doublier; Chiara Riganti; Claudia Voena; Costanzo Costamagna; Elisabetta Aldieri; Gianpiero Pescarmona; Dario Ghigo; Amalia Bosia
Journal:  Mol Cancer Res       Date:  2008-10       Impact factor: 5.852

Review 7.  The enigma of nitroglycerin bioactivation and nitrate tolerance: news, views and troubles.

Authors:  B Mayer; M Beretta
Journal:  Br J Pharmacol       Date:  2008-06-23       Impact factor: 8.739

8.  Doxorubicin induces an increase of nitric oxide synthesis in rat cardiac cells that is inhibited by iron supplementation.

Authors:  Elisabetta Aldieri; Loredana Bergandi; Chiara Riganti; Costanzo Costamagna; Amalia Bosia; Dario Ghigo
Journal:  Toxicol Appl Pharmacol       Date:  2002-12-01       Impact factor: 4.219

Review 9.  Targeting multidrug resistance in cancer.

Authors:  Gergely Szakács; Jill K Paterson; Joseph A Ludwig; Catherine Booth-Genthe; Michael M Gottesman
Journal:  Nat Rev Drug Discov       Date:  2006-03       Impact factor: 84.694

Review 10.  New insights into bioactivation of organic nitrates, nitrate tolerance and cross-tolerance.

Authors:  A Daiber; P Wenzel; M Oelze; T Münzel
Journal:  Clin Res Cardiol       Date:  2007-10-19       Impact factor: 5.460
View more
  13 in total

Review 1.  Mitochondria-targeting drug conjugates for cytotoxic, anti-oxidizing and sensing purposes: current strategies and future perspectives.

Authors:  Gantumur Battogtokh; Yeon Su Choi; Dong Seop Kang; Sang Jun Park; Min Suk Shim; Kang Moo Huh; Yong-Yeon Cho; Joo Young Lee; Hye Suk Lee; Han Chang Kang
Journal:  Acta Pharm Sin B       Date:  2018-05-18       Impact factor: 11.413

2.  Novel Nitric Oxide Donors of Phenylsulfonylfuroxan and 3-Benzyl Coumarin Derivatives as Potent Antitumor Agents.

Authors:  Yalan Guo; Yujie Wang; Haihong Li; Ke Wang; Qi Wan; Jia Li; Yubo Zhou; Ying Chen
Journal:  ACS Med Chem Lett       Date:  2018-04-20       Impact factor: 4.345

3.  Light-Regulated NO Release as a Novel Strategy To Overcome Doxorubicin Multidrug Resistance.

Authors:  Konstantin Chegaev; Aurore Fraix; Elena Gazzano; Gamal Eldein F Abd-Ellatef; Marco Blangetti; Barbara Rolando; Sabrina Conoci; Chiara Riganti; Roberta Fruttero; Alberto Gasco; Salvatore Sortino
Journal:  ACS Med Chem Lett       Date:  2017-01-30       Impact factor: 4.345

4.  Synthesis and Antiproliferative Activity of Nitric Oxide-Donor Largazole Prodrugs.

Authors:  Matteo Borgini; Claudio Zamperini; Federica Poggialini; Luca Ferrante; Vincenzo Summa; Maurizio Botta; Romano Di Fabio
Journal:  ACS Med Chem Lett       Date:  2020-02-07       Impact factor: 4.345

5.  New praziquantel derivatives containing NO-donor furoxans and related furazans as active agents against Schistosoma mansoni.

Authors:  Stefano Guglielmo; Daniela Cortese; Francesca Vottero; Barbara Rolando; Valerie P Kommer; David L Williams; Roberta Fruttero; Alberto Gasco
Journal:  Eur J Med Chem       Date:  2014-07-03       Impact factor: 6.514

6.  New NO- and H2S-releasing doxorubicins as targeted therapy against chemoresistance in castration-resistant prostate cancer: in vitro and in vivo evaluations.

Authors:  Elisabetta Bigagli; Cristina Luceri; Maria De Angioletti; Konstantin Chegaev; Mario D'Ambrosio; Chiara Riganti; Elena Gazzano; Simona Saponara; Mariangela Longini; Francesca Luceri; Lorenzo Cinci
Journal:  Invest New Drugs       Date:  2018-04-02       Impact factor: 3.850

7.  Temporal inhibition of mouse mammary gland cancer metastasis by CORM-A1 and DETA/NO combination therapy.

Authors:  Kseniia Porshneva; Diana Papiernik; Mateusz Psurski; Agnieszka Łupicka-Słowik; Rafał Matkowski; Marcin Ekiert; Marcin Nowak; Joanna Jarosz; Joanna Banach; Magdalena Milczarek; Tomasz M Goszczyński; Marcin Sieńczyk; Joanna Wietrzyk
Journal:  Theranostics       Date:  2019-05-31       Impact factor: 11.556

8.  Synthesis and Antitumor Evaluation of Novel Hybrids of Phenylsulfonylfuroxan and Estradiol Derivatives.

Authors:  Qi Wan; Yan Deng; Yaoqing Huang; Zhihui Yu; Chunli Wang; Ke Wang; Jibin Dong; Ying Chen
Journal:  ChemistryOpen       Date:  2019-12-11       Impact factor: 2.911

Review 9.  S-Nitrosylation in Tumor Microenvironment.

Authors:  Vandana Sharma; Veani Fernando; Joshua Letson; Yashna Walia; Xunzhen Zheng; Daniel Fackelman; Saori Furuta
Journal:  Int J Mol Sci       Date:  2021-04-27       Impact factor: 5.923

Review 10.  Exploring new Horizons in overcoming P-glycoprotein-mediated multidrug-resistant breast cancer via nanoscale drug delivery platforms.

Authors:  Paras Famta; Saurabh Shah; Essha Chatterjee; Hoshiyar Singh; Biswajit Dey; Santosh Kumar Guru; Shashi Bala Singh; Saurabh Srivastava
Journal:  Curr Res Pharmacol Drug Discov       Date:  2021-09-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.